Clinical trial with Gilteritinib for patients with FLT3/ITD-positive AML opens in Freiburg

At the center in Freiburg, a phase I/II trial with Gilteritinib for the treatment of children, adolescents and young adults with FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) relapsed or refractory Acute Myeloid Leukemia (AML) has been launched in September 2020. Patients between 6 months and 21 years are eligible for this trial. The investigators want to find the safest dose of Gilteritinib that can be given and to learn which effects the study drug have on the cancer and the body. More information about this trial can be found on ClinicalTrials.gov (NCT04240002).